細胞株作製の世界市場:細胞株作製装置、培地、血清、試薬

◆英語タイトル:Cell Line Development Market by Product (Equipment, Media and Reagents), Source, type & by Application ( Bioproduction, Tissue Engineering & Regenerative medicine, Toxicity Testing, Research, Drug Discovery) - Analysis & Global Forecast to 2019
◆商品コード:MAM-BT2750
◆発行会社(調査会社):MarketsandMarkets
◆発行日:2014年9月
◆ページ数:220
◆レポート言語:英語
◆レポート形式:pdf
◆納品方法:Eメール
◆調査対象地域:グローバル
◆産業分野:バイオ技術
◆販売価格オプション(消費税別)
Single user(1名使用)USD5,650 ⇒換算¥570,650見積依頼/購入/質問フォーム
Multi User(5名まで使用)USD6,650 ⇒換算¥671,650見積依頼/購入/質問フォーム
Corporate licence(全社内共有可)USD8,150 ⇒換算¥823,150見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日~2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送いたしますので、請求書発行日より2ヶ月以内に銀行振込にて支払をお願いします。(支払期限と方法は調整可能、振込先:三菱東京UFJ銀行/京橋支店/H&Iグローバルリサーチ株式会社)
※レポート購入後、該当レポートに記載の英語表現や単語の意味に関しましては無料でお答えいたします。(但し、対応範囲は弊社で判断)
※上記の日本語題名はH&Iグローバルリサーチが翻訳したものです。英語版原本には日本語表記はありません。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はMarketsandMarkets社の日本における正規販売代理店です。MarketsandMarkets社の概要及び新刊レポートはこちらでご確認いただけます。



【レポートの概要】

Over the years, the cell line development market has witnessed various technological advancements in order to cater to the growing demand for stable and high-yielding cell lines. These advancements have led to growth in a number of applications of cell lines such as bioproduction, tissue engineering and regenerative medicine, toxicity testing, research, and drug discovery.

Cell line development media and reagents account for the largest share in the global cell line development market, as they have numerous applications in areas such as bioproduction, tissue engineering and regenerative medicine, toxicity testing, research, and drug discovery. The reagents segment accounted for the maximum share of the cell line development media and reagents market. The bioproduction segment accounted for the largest share of the cell line development application market, as cell lines are extensively used in diagnostics, vaccine production, and in manufacturing of recombinant protein therapeutics.

North America accounted for the largest share of the global cell line development market, followed by Europe, Asia, and the Rest of the World (RoW). In the coming years, the cell line development market is expected to experience the highest growth rate in the Asian region, with emphasis on India, China, and Japan. These countries are expected to serve as revenue pockets for cell line manufacturers.

The global cell line development market witnesses high competitive intensity as there are several big and many small firms with similar product offerings. These companies adopt various strategies (innovations, acquisitions, and geographical expansions) to increase their market shares and to establish a strong foothold in the global market.

Reasons to Buy the Report:

The report will enrich both established firms as well as new entrants/smaller firms to gauge the pulse of the market, which in turn helps the firms garner a greater market share. Firms purchasing the report could use any one or a combination of the below mentioned five strategies (market penetration, product development/innovation, market development, market diversification, and competitive assessment) for strengthening their market shares.

The report provides insights on the following pointers:

• Market Penetration: Comprehensive information on the product portfolios and services offered by the top players in the cell line development market. The report analyzes cell line development products by equipment and media and reagents

• Product Development/Innovation: Detailed insights on the upcoming technologies, research and development activities, and new product launches in the cell line development market

• Market Development: Comprehensive information about the lucrative emerging markets. The report analyzes the markets for various cell line development technologies across geographies

• Market Diversification: Exhaustive information about new products and services, untapped geographies, recent developments, and investments in the cell line development market

• Competitive Assessment: In-depth assessment of the market shares, strategies, products and services, distribution networks, and manufacturing capabilities of the leading players in the cell line development market

【レポートの目次】

TABLE OF CONTENTS

1 INTRODUCTION 20
1.1 OBJECTIVES OF THE STUDY 20
1.2 MARKET SCOPE 20
1.3 STAKEHOLDERS 23

2 RESEARCH METHODOLOGY 24
2.1 SECONDARY AND PRIMARY RESEARCH METHODOLOGY 24
2.1.1 SECONDARY RESEARCH 24
2.1.1.1 key data from secondary sources 25
2.1.2 PRIMARY RESEARCH 26
2.1.2.1 Key Industry Insights 26
2.1.2.2 key data from primary sources 28
2.1.2.3 key Insights from primary sources 28
2.1.3 MARKET SIZE ESTIMATION METHODOLOGY 29
2.1.4 MARKET FORECAST METHODOLOGY 31
2.1.5 MARKET DATA VALIDATION AND DATA TRIANGULATION 31
2.1.6 ASSUMPTIONS 32
2.1.7 LIMITATIONS 33

3 EXECUTIVE SUMMARY 34

4 PREMIUM INSIGHTS 38
4.1 GLOBAL CELL LINE DEVELOPMENT MARKET SIZE 38
4.2 CELL LINE DEVELOPMENT MARKET, BY GEOGRAPHY AND TYPE 39
4.3 GEOGRAPHICAL SNAPSHOT 40
4.4 MARKET SHARE, BY PRODUCT 40
4.5 LIFE CYCLE ANALYSIS, BY GEOGRAPHY 41

5 MARKET OVERVIEW 42
5.1 INTRODUCTION 43
5.2 MARKET DYNAMICS 43
5.2.1 DRIVERS 44
5.2.1.1 Global increase in demand for monoclonal antibodies 44
5.2.1.2 Innovative technologies accelerating the scale-up of cell lines 44
5.2.1.3 Rise in vaccine production 45
5.2.2 CHALLENGES 46
5.2.2.1 Developing stable and authentic cell lines 46
5.2.3 OPPORTUNITIES 47
5.2.3.1 Increasing risk of pandemics and communicable diseases 47
5.2.3.2 Low-income countries to create opportunities for the cell line development market 47

6 INDUSTRY INSIGHTS 49
6.1 INTRODUCTION 49
6.2 COMPETITIVE POSITIONING, BY KEY PLAYER (2014) 49
6.2.1 INTRODUCTION 49
6.2.2 KEY HIGHLIGHTS 51
6.3 CELL LINE DEVELOPMENT MARKET: EMPIRICAL ASSESSMENT OF GROWTH STRATEGIES 53
6.3.1 ROUTE TO STRATEGIC GROWTH: ORGANIC OR INORGANIC GROWTH 53
6.3.2 ORGANIC GROWTH STRATEGIES 54
6.3.3 INORGANIC GROWTH STRATEGIES 55
6.4 TECHNOLOGY ASSESSMENT 57
6.4.1 EXPRESSION SYSTEMS 58
6.4.1.1 Methotrexate Amplification (DHFR) Technology 59
6.4.1.2 Glutamine Synthatase (GS) Technology 59
6.4.1.3 Viral-based Technology 59

7 GLOBAL CELL LINE DEVELOPMENT MARKET, BY PRODUCT 61
7.1 CELL LINE DEVELOPMENT MARKET, BY PRODUCT 62
7.2 GLOBAL CELL LINE DEVELOPMENT MARKET, BY EQUIPMENT 63
7.2.1 INTRODUCTION 63
7.2.2 BIOSAFETY CABINETS 66
7.2.3 CELL COUNTERS & VIABILITY ANALYSIS SYSTEMS 67
7.2.4 INCUBATORS 68
7.2.5 CENTRIFUGES 69
7.2.6 BIOREACTORS 70
7.2.7 STORAGE EQUIPMENT 71
7.2.7.1 Refrigerators & Freezers 72
7.2.7.2 Cryostorage Systems 73
7.2.8 AUTOMATION SYSTEMS 74
7.2.9 MICROSCOPES 75
7.2.10 FILTRATION SYSTEMS 76
7.2.11 OTHER EQUIPMENT 77
7.3 GLOBAL CELL LINE DEVELOPMENT MARKET, BY MEDIA & REAGENTS 79
7.3.1 INTRODUCTION 79
7.3.2 CELL LINE MEDIA & REAGENTS 81
7.3.2.1 Sera 81
7.3.2.1.1 Fetal Bovine Sera (FBS) 84
7.3.2.1.2 Adult Bovine Sera (ABS) 85
7.3.2.1.3 Other Animal Sera 85
7.3.2.2 Media 86
7.3.2.2.1 Minimum Essential Media (MEM) 88
7.3.2.2.2 Reduced Serum Media 89
7.3.2.2.3 Serum-Free Media (SFM) 90
7.3.2.3 REAGENTS 91
7.3.2.3.1 Supplements & Growth Factors 93
7.3.2.3.2 Buffers & Chemicals 94
7.3.2.3.3 Cell Dissociation Reagents 95
7.3.2.3.4 Cryopreservative Reagents 96
7.3.2.3.5 Other Reagents 97

8 CELL LINE DEVELOPMENT MARKET, BY SOURCE 98
8.1 INTRODUCTION 99
8.1.1 MAMMALIAN 100
8.1.2 INSECT 101
8.1.3 AMPHIBIAN 103

9 CELL LINE DEVELOPMENT MARKET, BY TYPE 104
9.1 INTRODUCTION 105
9.1.1 PRIMARY CELL LINES 106
9.1.2 CONTINUOUS CELL LINES 107
9.1.3 HYBRIDOMAS 108
9.1.4 RECOMBINANT CELL LINES 110

10 GLOBAL CELL LINE DEVELOPMENT MARKET, BY APPLICATION 112
10.1 INTRODUCTION 113
10.2 BIOPRODUCTION 116
10.2.1 DIAGNOSTICS 117
10.2.2 VACCINE PRODUCTION 118
10.2.3 RECOMBINANT PROTEIN THERAPEUTICS 119
10.3 TISSUE ENGINEERING & REGENERATIVE MEDICINE 120
10.4 TOXICITY TESTING 120
10.5 RESEARCH 121
10.6 DRUG DISCOVERY 122
10.6.1 TARGET VALIDATION 122
10.6.2 DISEASE MODELING 122
10.6.3 DRUG SCREENING AND DEVELOPMENT 123

11 CELL LINE DEVELOPMENT MARKET, BY GEOGRAPHY 124
11.1 INTRODUCTION 125
11.2 NORTH AMERICA 127
11.2.1 U.S. 131
11.2.1.1 R&D Investments by Pharmaceutical Companies in the U.S. to Propel the Cell Line Development Market 131
11.2.1.2 Rise in Funding for Vaccine Production likely to Fuel Demand of Cell Line Development Market 133
11.2.1.3 Conferences on Cell Line Development to Propel Growth of Market 133
11.2.2 CANADA 133
11.2.2.1 Increasing Investments on Regenerative Medicines by Canadian Government to Spur the Market 133
11.3 EUROPE 136
11.3.1 FLOURISHING VACCINE MARKET IN EUROPE—A MAJOR PROPELLANT FOR THE CELL LINE DEVELOPMENT MARKET 137
11.3.2 FRANCE 140
11.3.2.1 Increasing Use of Cell Lines for Vaccine Production to Spur Market in France 140
11.3.3 GERMANY 142
11.3.3.1 Advances in Biotechnology Fueling the Cell Line Development Market in Germany 142
11.3.4 U.K. 144
11.3.4.1 Conferences on Cell Line Development to Spur Market in the U.K. 144
11.3.5 REST OF EUROPE (ROE) 146
11.3.5.1 Increasing Research on Regenerative Medicines in Spain to Propel the Cell Line Development Market 146
11.4 ASIA 149
11.4.1 INDIA 149
11.4.1.1 Growing Pharmaceutical Industry to Propel the Market in India 149
11.4.2 CHINA 150
11.4.2.1 Developing Pharmaceutical Industry to Spur the Market in China 150
11.4.3 JAPAN 150
11.4.3.1 Rise in Production of Vaccines in Japan to Propel the Use of Cell Lines 150
11.4.3.2 Regenerative Medicine, Biomedical, and Medical Research in Japan is on the Rise 150
11.4.4 REST OF ASIA (ROA) 151
11.4.4.1 Initiation of Measles-Rubella Combined Vaccine Production in Vietnam 151
11.4.4.2 Government-Supported Strong Academic and Commercial R&D Activities in Taiwan 151
11.5 REST OF THE WORLD (ROW) 155
11.5.1 PACIFIC COUNTRIES 156
11.5.1.1 Federal Collaborations in Australia to Bolster the Demand of Cell Lines 156
11.5.1.2 Favorable Regulatory Changes to Drive the Market in New Zealand and Australia 156
11.5.2 BRAZIL 156
11.5.2.1 Flourishing Biotechnology and Pharmaceutical Markets in Brazil to Bolster the Cell Line Development Market 156
11.5.3 AFRICA 157
11.5.3.1 Increasing Focus on Africa by Pharmaceutical Companies Likely to Create Avenues for Cell Line Development Market 157

12 COMPETITIVE LANDSCAPE 161
12.1 OVERVIEW 161
12.2 MARKET SHARE ANALYSIS, CELL LINE DEVELOPMENT MARKET 162
12.2.1 INTRODUCTION 162
12.2.1.1 American Type Culture Collection (ATCC) (U.S.) 162
12.2.1.2 Lonza Group AG (Switzerland) 163
12.2.1.3 Thermo Fisher Scientific, Inc. (U.S.) 163
12.3 COMPETITIVE SITUATION AND TRENDS 164
12.3.1 AGREEMENTS, PARTNERSHIPS, AND COLLABORATIONS 166
12.3.2 NEW PRODUCT LAUNCHES 168
12.3.3 EXPANSIONS 169
12.3.4 ACQUISITIONS 170
12.3.5 OTHERS 171

13 COMPANY PROFILES 173
(Overview, Financials, Products & Services, Strategy, & Developments)*
13.1 INTRODUCTION 173
13.2 AMERICAN TYPE CULTURE COLLECTION (ATCC) 174
13.3 CORNING, INC. 178
13.4 EUROPEAN COLLECTION OF CELL CULTURES (ECACC) 182
13.5 GE HEALTHCARE 184
13.6 LONZA GROUP AG 188
13.7 SARTORIUS AG 193
13.8 SELEXIS SA 196
13.9 SIGMA-ALDRICH CORPORATION 200
13.10 THERMO FISHER SCIENTIFIC, INC. 206
13.11 WUXI APPTEC 211
*Details on Financials, Product & Services, Strategy, & Developments might not be captured in case of unlisted companies.

14 APPENDIX 213
14.1 DISCUSSION GUIDE 213
14.2 INTRODUCING RT: REAL TIME MARKET INTELLIGENCE 216
14.3 AVAILABLE CUSTOMIZATIONS 217
14.4 RELATED REPORTS 218

LIST OF TABLES

TABLE 1 DRIVERS PROPELLING THE GROWTH OF THE CELL LINE DEVELOPMENT MARKET 46
TABLE 2 MAJOR CHALLENGE IN THE CELL LINE DEVELOPMENT MARKET 47
TABLE 3 MAJOR GROWTH OPPORTUNITIES IN THE CELL LINE DEVELOPMENT MARKET 48
TABLE 4 CELL LINE DEVELOPMENT MARKET SIZE, BY PRODUCT, 2012–2019 ($MILLION) 62
TABLE 5 CELL LINE DEVELOPMENT MARKET SIZE FOR EQUIPMENT, BY REGION,
2012–2019 ($MILLION) 64
TABLE 6 CELL LINE DEVELOPMENT MARKET SIZE, BY EQUIPMENT, 2012–2019 ($MILLION) 65
TABLE 7 CELL LINE DEVELOPMENT MARKET SIZE FOR BIOSAFETY CABINETS, BY REGION, 2012–2019 ($MILLION) 67
TABLE 8 CELL LINE DEVELOPMENT MARKET SIZE FOR CELL COUNTERS & VIABILITY ANALYSIS SYSTEMS, BY REGION, 2012–2019 ($MILLION) 68
TABLE 9 CELL LINE DEVELOPMENT MARKET SIZE FOR INCUBATORS, BY REGION,
2012–2019 ($MILLION) 69
TABLE 10 CELL LINE DEVELOPMENT MARKET SIZE FOR CENTRIFUGES, BY REGION,
2012–2019 ($MILLION) 69
TABLE 11 CELL LINE DEVELOPMENT MARKET SIZE FOR BIOREACTORS, BY REGION,
2012–2019 ($MILLION) 70
TABLE 12 CELL LINE DEVELOPMENT MARKET SIZE FOR STORAGE EQUIPMENT, BY REGION, 2012–2019 ($MILLION) 71
TABLE 13 CELL LINE DEVELOPMENT MARKET SIZE FOR STORAGE EQUIPMENT, BY SEGMENT, 2012–2019 ($MILLION) 71
TABLE 14 CELL LINE DEVELOPMENT MARKET SIZE FOR REFRIGERATORS & FREEZERS,
BY REGION, 2012–2019 ($MILLION) 73
TABLE 15 CELL LINE DEVELOPMENT MARKET SIZE FOR CRYOSTORAGE SYSTEMS,
BY REGION, 2012–2019 ($MILLION) 74
TABLE 16 CELL LINE DEVELOPMENT MARKET SIZE FOR AUTOMATION SYSTEMS, BY REGION, 2012–2019 ($MILLION) 75
TABLE 17 CELL LINE DEVELOPMENT MARKET SIZE FOR MICROSCOPES, BY REGION,
2012–2019 ($MILLION) 76
TABLE 18 CELL LINE DEVELOPMENT MARKET SIZE FOR FILTRATION SYSTEMS, BY REGION, 2012–2019 ($MILLION) 77
TABLE 19 CELL LINE DEVELOPMENT MARKET SIZE FOR OTHER EQUIPMENT, BY REGION, 2012–2019 ($MILLION) 78
TABLE 20 CELL LINE DEVELOPMENT MARKET SIZE FOR MEDIA & REAGENTS, BY SEGMENT, 2012–2019 ($MILLION) 79
TABLE 21 CELL LINE DEVELOPMENT MARKET SIZE FOR MEDIA & REAGENTS, BY REGION, 2012–2019 ($MILLION) 80
TABLE 22 CELL LINE DEVELOPMENT MARKET SIZE FOR SERA, BY REGION,
2012–2019 ($MILLION) 82
TABLE 23 CELL LINE DEVELOPMENT MARKET SIZE FOR SERA, BY SEGMENT,
2012–2019 ($MILLION) 83
TABLE 24 CELL LINE DEVELOPMENT MARKET SIZE FOR FETAL BOVINE SERA, BY REGION, 2012–2019 ($MILLION) 84
TABLE 25 CELL LINE DEVELOPMENT MARKET SIZE FOR ADULT BOVINE SERA, BY REGION, 2012–2019 ($MILLION) 85
TABLE 26 CELL LINE DEVELOPMENT MARKET SIZE FOR OTHER ANIMAL SERA, BY REGION, 2012–2019 ($MILLION) 86
TABLE 27 CELL LINE DEVELOPMENT MARKET SIZE FOR MEDIA, BY REGION,
2012–2019 ($MILLION) 86
TABLE 28 CELL LINE DEVELOPMENT MARKET SIZE FOR MEDIA, BY SEGMENT,
2012–2019 ($MILLION) 87
TABLE 29 CELL LINE DEVELOPMENT MARKET SIZE FOR MINIMUM ESSENTIAL MEDIA,
BY REGION, 2012–2019 ($MILLION) 89
TABLE 30 CELL LINE DEVELOPMENT MARKET SIZE FOR REDUCED SERUM MEDIA,
BY REGION, 2012–2019 ($MILLION) 90
TABLE 31 CELL LINE DEVELOPMENT MARKET SIZE FOR SERUM-FREE MEDIA, BY REGION, 2012–2019 ($MILLION) 91
TABLE 32 CELL LINE DEVELOPMENT MARKET SIZE FOR REAGENTS, BY REGION,
2012–2019 ($MILLION) 91
TABLE 33 CELL LINE DEVELOPMENT MARKET SIZE FOR REAGENTS, BY SEGMENT,
2012–2019 ($MILLION) 92
TABLE 34 CELL LINE DEVELOPMENT MARKET SIZE FOR SUPPLEMENTS & GROWTH FACTORS, BY REGION, 2012–2019 ($MILLION) 94
TABLE 35 CELL LINE DEVELOPMENT MARKET SIZE FOR BUFFERS & CHEMICALS, BY REGION, 2012–2019 ($MILLION) 95
TABLE 36 CELL LINE DEVELOPMENT MARKET SIZE FOR CELL DISSOCIATION REAGENTS,
BY REGION, 2012–2019 ($MILLION) 96
TABLE 37 CELL LINE DEVELOPMENT MARKET SIZE FOR CRYOPRESERVATIVE REAGENTS,
BY REGION, 2012–2019 ($MILLION) 96
TABLE 38 CELL LINE DEVELOPMENT MARKET SIZE FOR OTHER REAGENTS, BY REGION, 2012–2019 ($MILLION) 97
TABLE 39 CELL LINE DEVELOPMENT MARKET SIZE, BY SOURCE, 2012–2019 ($MILLION) 99
TABLE 40 TYPES OF MAMMALIAN CELL LINES AND THEIR APPLICATIONS 100
TABLE 41 CELL LINE DEVELOPMENT MARKET SIZE FOR MAMMALIAN SOURCES, BY REGION, 2012–2019 ($MILLION) 101
TABLE 42 CELL LINE DEVELOPMENT MARKET SIZE FOR INSECT SOURCES, BY REGION, 2012–2019 ($MILLION) 102
TABLE 43 CELL LINE DEVELOPMENT MARKET SIZE FOR AMPHIBIAN SOURCES, BY REGION, 2012–2019 ($MILLION) 103
TABLE 44 CELL LINE DEVELOPMENT MARKET SIZE, BY TYPE, 2012–2019 ($MILLION) 106
TABLE 45 CELL LINE DEVELOPMENT MARKET SIZE FOR PRIMARY CELL LINES, BY REGION, 2012–2019 ($MILLION) 106
TABLE 46 CELL LINE DEVELOPMENT MARKET SIZE FOR CONTINUOUS CELL LINES,
BY REGION, 2012–2019 ($MILLION) 107
TABLE 47 CELL LINE DEVELOPMENT MARKET SIZE FOR HYBRIDOMAS, BY REGION,
2012–2019 ($MILLION) 109
TABLE 48 BIOLOGICS PRODUCED USING CHO CELLS (2006-2012) 110
TABLE 49 CELL LINE DEVELOPMENT MARKET SIZE FOR RECOMBINANT CELL LINES,
BY REGION, 2012–2019 ($MILLION) 111
TABLE 50 CELL LINE DEVELOPMENT APPLICATIONS MARKET SIZE, BY REGION,
2012–2019 ($MILLION) 114
TABLE 51 CELL LINE DEVELOPMENT MARKET SIZE, BY APPLICATION,
2012–2019 ($MILLION) 115
TABLE 52 CELL LINE DEVELOPMENT MARKET SIZE FOR BIOPRODUCTION, BY REGION, 2012–2019 ($MILLION) 116
TABLE 53 CELL LINE DEVELOPMENT MARKET SIZE FOR BIOPRODUCTION, BY SEGMENT, 2012–2019 ($MILLION) 116
TABLE 54 CELL LINE DEVELOPMENT MARKET SIZE FOR DIAGNOSTICS, BY REGION,
2012–2019 ($MILLION) 118
TABLE 55 CELL LINE DEVELOPMENT MARKET SIZE FOR VACCINE PRODUCTION, BY REGION, 2012–2019 ($MILLION) 119
TABLE 56 CELL LINE DEVELOPMENT MARKET SIZE FOR RECOMBINANT PROTEIN THERAPEUTICS, BY REGION, 2012–2019 ($MILLION) 119
TABLE 57 CELL LINE DEVELOPMENT MARKET SIZE FOR TISSUE ENGINEERING & REGENERATIVE MEDICINE, BY REGION, 2012–2019 ($MILLION) 120
TABLE 58 CELL LINE DEVELOPMENT MARKET SIZE FOR TOXICITY TESTING, BY REGION, 2012–2019 ($MILLION) 121
TABLE 59 CELL LINE DEVELOPMENT MARKET SIZE FOR RESEARCH APPLICATIONS,
BY REGION, 2012–2019 ($MILLION) 121
TABLE 60 CELL LINE DEVELOPMENT MARKET SIZE FOR DRUG DISCOVERY, BY REGION, 2012–2019 ($MILLION) 122
TABLE 61 CELL LINE DEVELOPMENT MARKET SIZE, BY REGION, 2012–2019 ($MILLION) 125
TABLE 62 NORTH AMERICA: CELL LINE DEVELOPMENT MARKET SIZE, BY PRODUCT,
2012–2019 ($MILLION) 128
TABLE 63 NORTH AMERICA: CELL LINE DEVELOPMENT EQUIPMENT MARKET SIZE,
2012–2019 ($MILLION) 128
TABLE 64 NORTH AMERICA: CELL LINE DEVELOPMENT MEDIA & REAGENTS MARKET SIZE, 2012–2019 ($MILLION) 129
TABLE 65 NORTH AMERICA: CELL LINE DEVELOPMENT MARKET SIZE, BY SOURCE,
2012–2019 ($MILLION) 129
TABLE 66 NORTH AMERICA: CELL LINE DEVELOPMENT MARKET SIZE, BY TYPE,
2012–2019 ($MILLION) 130
TABLE 67 NORTH AMERICA: CELL LINE DEVELOPMENT MARKET SIZE, BY APPLICATION, 2012–2019 ($MILLION) 130
TABLE 68 U.S.: CELL LINE DEVELOPMENT MARKET SIZE, BY PRODUCT,
2012–2019 ($MILLION) 131
TABLE 69 U.S.: CELL LINE DEVELOPMENT MARKET SIZE, BY SOURCE,
2012–2019 ($MILLION) 131
TABLE 70 U.S.: CELL LINE DEVELOPMENT MARKET SIZE, BY TYPE, 2012–2019 ($MILLION) 132
TABLE 71 U.S.: CELL LINE DEVELOPMENT MARKET SIZE, BY APPLICATION,
2012–2019 ($MILLION) 132
TABLE 72 CANADA: CELL LINE DEVELOPMENT MARKET SIZE, BY PRODUCT,
2012–2019 ($MILLION) 134
TABLE 73 CANADA: CELL LINE DEVELOPMENT MARKET SIZE, BY SOURCE,
2012–2019 ($MILLION) 134
TABLE 74 CANADA: CELL LINE DEVELOPMENT MARKET SIZE, BY TYPE,
2012–2019 ($MILLION) 135
TABLE 75 CANADA: CELL LINE DEVELOPMENT MARKET SIZE, BY APPLICATION,
2012–2019 ($MILLION) 135
TABLE 76 EUROPE: CELL LINE DEVELOPMENT MARKET SIZE, BY PRODUCT,
2012–2019 ($MILLION) 137
TABLE 77 EUROPE: CELL LINE DEVELOPMENT EQUIPMENT MARKET SIZE,
2012–2019 ($MILLION) 138
TABLE 78 EUROPE: CELL LINE DEVELOPMENT MEDIA & REAGENTS MARKET SIZE,
2012–2019 ($MILLION) 138
TABLE 79 EUROPE: CELL LINE DEVELOPMENT MARKET SIZE, BY SOURCE,
2012–2019 ($MILLION) 139
TABLE 80 EUROPE: CELL LINE DEVELOPMENT MARKET SIZE, BY TYPE,
2012–2019 ($MILLION) 139
TABLE 81 EUROPE: CELL LINE DEVELOPMENT MARKET SIZE, BY APPLICATION,
2012–2019 ($MILLION) 140
TABLE 82 FRANCE: CELL LINE DEVELOPMENT MARKET SIZE, BY PRODUCT,
2012–2019 ($MILLION) 140
TABLE 83 FRANCE: CELL LINE DEVELOPMENT MARKET SIZE, BY SOURCE,
2012–2019 ($MILLION) 141
TABLE 84 FRANCE: CELL LINE DEVELOPMENT MARKET SIZE, BY TYPE,
2012–2019 ($MILLION) 141
TABLE 85 FRANCE: CELL LINE DEVELOPMENT MARKET SIZE, BY APPLICATION,
2012–2019 ($MILLION) 142
TABLE 86 GERMANY: CELL LINE DEVELOPMENT MARKET SIZE, BY PRODUCT,
2012–2019 ($MILLION) 142
TABLE 87 GERMANY: CELL LINE DEVELOPMENT MARKET SIZE, BY SOURCE,
2012–2019 ($MILLION) 143
TABLE 88 GERMANY: CELL LINE DEVELOPMENT MARKET SIZE, BY TYPE,
2012–2019 ($MILLION) 143
TABLE 89 GERMANY: CELL LINE DEVELOPMENT MARKET SIZE, BY APPLICATION,
2012–2019 ($MILLION) 144
TABLE 90 U.K.: CELL LINE DEVELOPMENT MARKET SIZE, BY PRODUCT,
2012–2019 ($MILLION) 144
TABLE 91 U.K.: CELL LINE DEVELOPMENT MARKET SIZE, BY SOURCE,
2012–2019 ($MILLION) 145
TABLE 92 U.K.: CELL LINE DEVELOPMENT MARKET SIZE, BY TYPE, 2012–2019 ($MILLION) 145
TABLE 93 U.K.: CELL LINE DEVELOPMENT MARKET SIZE, BY APPLICATION,
2012–2019 ($MILLION) 146
TABLE 94 ROE: CELL LINE DEVELOPMENT MARKET SIZE, BY PRODUCT,
2012–2019 ($MILLION) 147
TABLE 95 ROE: CELL LINE DEVELOPMENT MARKET SIZE, BY SOURCE,
2012–2019 ($MILLION) 147
TABLE 96 ROE: CELL LINE DEVELOPMENT MARKET SIZE, BY TYPE, 2012–2019 ($MILLION) 147
TABLE 97 ROE: CELL LINE DEVELOPMENT MARKET SIZE, BY APPLICATION,
2012–2019 ($MILLION) 148
TABLE 98 ASIA: CELL LINE DEVELOPMENT MARKET SIZE, BY PRODUCT,
2012–2019 ($MILLION) 151
TABLE 99 ASIA: CELL LINE DEVELOPMENT EQUIPMENT MARKET SIZE,
2012–2019 ($MILLION) 152
TABLE 100 ASIA: CELL LINE DEVELOPMENT MEDIA & REAGENTS MARKET SIZE,
2012–2019 ($MILLION) 152
TABLE 101 ASIA: CELL LINE DEVELOPMENT MARKET SIZE, BY SOURCE,
2012–2019 ($MILLION) 153
TABLE 102 ASIA: CELL LINE DEVELOPMENT MARKET SIZE, BY TYPE, 2012–2019 ($MILLION) 153
TABLE 103 ASIA: CELL LINE DEVELOPMENT MARKET SIZE, BY APPLICATION,
2012–2019 ($MILLION) 154
TABLE 104 ROW: CELL LINE DEVELOPMENT MARKET SIZE, BY PRODUCT,
2012–2019 ($MILLION) 157
TABLE 105 ROW: CELL LINE DEVELOPMENT EQUIPMENT MARKET SIZE,
2012–2019 ($MILLION) 158
TABLE 106 ROW: CELL LINE DEVELOPMENT MEDIA & REAGENTS MARKET SIZE,
2012–2019 ($MILLION) 158
TABLE 107 ROW: CELL LINE DEVELOPMENT MARKET SIZE, BY SOURCE,
2012–2019 ($MILLION) 159
TABLE 108 ROW: CELL LINE DEVELOPMENT MARKET SIZE, BY TYPE, 2012–2019 ($MILLION) 159
TABLE 109 ROW: CELL LINE DEVELOPMENT MARKET SIZE, BY APPLICATION,
2012–2019 ($MILLION) 160
TABLE 110 AGREEMENTS, PARTNERSHIPS, AND COLLABORATIONS 2011–2014 167
TABLE 111 NEW PRODUCT LAUNCHES, 2011–2013 168
TABLE 112 EXPANSIONS, 2011–2014 169
TABLE 113 ACQUISITIONS, 2011–2014 170
TABLE 114 OTHERS, 2011–2014 171

LIST OF FIGURES

FIGURE 1 CELL LINE DEVELOPMENT MARKET SEGMENTATION 21
FIGURE 2 GLOBAL CELL LINE DEVELOPMENT : RESEARCH METHODOLOGY STEPS 24
FIGURE 3 SAMPLING FRAME: PRIMARY RESEARCH 27
FIGURE 4 BREAK DOWN OF PRIMARY INTERVIEWS: BY COMPANY TYPE, DESIGNATION, AND REGION 27
FIGURE 5 MARKET SIZE ESTIMATION METHODOLOGY: BOTTOM-UP APPROACH 29
FIGURE 6 MARKET SIZE ESTIMATION METHODOLOGY: TOP-DOWN APPROACH 30
FIGURE 7 MARKET FORECAST METHODOLOGY 31
FIGURE 8 DATA TRIANGULATION METHODOLOGY 32
FIGURE 9 GLOBAL CELL LINE DEVELOPMENT MARKET SNAPSHOT, BY PRODUCT,
2014–2019 34
FIGURE 10 MEDIA AND REAGENTS MARKET TO WITNESS HIGHEST CAGR OF 13% FROM
2014 TO 2019 35
FIGURE 11 GLOBAL CELL LINE DEVELOPMENT MARKET SHARE, 2014 36
FIGURE 12 CELL LINE DEVELOPMENT: MARKET OVERVIEW 38
FIGURE 13 NORTH AMERICA ACCOUNTS FOR LARGEST SHARE OF MARKET; RECOMBINANT CELL LINES ACCOUNT FOR 68% OF MARKET, BY TYPE 39
FIGURE 14 ASIAN CELL LINE DEVELOPMENT MARKET TO GROW AT THE HIGHEST CAGR BETWEEN 2014 AND 2019 40
FIGURE 15 MEDIA AND REAGENTS TO COMMAND OVER 50% OF THE MARKET SHARE,
2014 VS. 2019 40
FIGURE 16 ROW IS EXPECTED TO ENTER THE EXPONENTIAL GROWTH PHASE IN THE COMING YEARS 41
FIGURE 17 INCREASING DEMAND FOR MONOCLONAL ANTIBODIES TO SPUR THE GROWTH IN THIS MARKET 43
FIGURE 18 COMPETITIVE POSITIONING, BY KEY PLAYER (2014) 50
FIGURE 19 COMPETITIVE POSITIONING, BY KEY PLAYER (2014) 51
FIGURE 20 ORGANIC AND INORGANIC GROWTH STRATEGIES 54
FIGURE 21 ORGANIC GROWTH STRATEGIES, BY KEY PLAYERS (2011–2014) 55
FIGURE 22 INORGANIC GROWTH STRATEGIES, BY KEY PLAYERS (2011–2014) 56
FIGURE 23 EVOLUTION OF CELL LINE DEVELOPMENT TECHNOLOGIES 57
FIGURE 24 COMPARATIVE TECHNOLOGY ASSESSMENT – CELL LINE DEVELOPMENT MARKET 58
FIGURE 25 THE MEDIA & REAGENTS SEGMENT IS EXPECTED TO GROW AT A FASTER PACE THAN THE EQUIPMENT SEGMENT FROM 2014 TO 2019 62
FIGURE 26 ASIA IS EXPECTED TO BE THE FASTEST-GROWING CELL LINE DEVELOPMENT MARKET AT A CAGR OF 14.6% FROM 2014 TO 2019 63
FIGURE 27 NORTH AMERICA IS EXPECTED TO ACCOUNT FOR THE LARGEST SHARE OF THE CELL LINE EQUIPMENT MARKET IN 2014 64
FIGURE 28 THE OTHER EQUIPMENT SEGMENT IS EXPECTED TO COMMAND THE LARGEST SHARE OF THE CELL LINE EQUIPMENT MARKET IN 2014 66
FIGURE 29 REFRIGERATORS & FREEZERS SEGMENT TO ACCOUNT FOR LARGEST SHARE (70%) OF STORAGE EQUIPMENT MARKET IN 2014 72
FIGURE 30 THE REAGENTS SEGMENT IS EXPECTED TO DOMINATE THE CELL LINE DEVELOPMENT MARKET 80
FIGURE 31 NORTH AMERICA IS EXPECTED TO BE THE LARGEST REGIONAL SEGMENT OF THE CELL LINE DEVELOPMENT MARKET FOR MEDIA & REAGENTS IN 2014 81
FIGURE 32 CELL LINE DEVELOPMENT MARKET FOR SERA, BY SEGMENT 82
FIGURE 33 THE FETAL BOVINE SERA SEGMENT IS EXPECTED TO COMMAND 60% OF THE CELL LINE DEVELOPMENT MARKET, GROWING AT THE HIGHEST CAGR OF 5.8% 83
FIGURE 34 CELL LINE DEVELOPMENT MARKET FOR MEDIA, BY SEGMENT 87
FIGURE 35 MINIMAL ESSENTIAL MEDIA TO GROW AT A HIGHER RATE FROM 2014 TO 2019 88
FIGURE 36 CELL LINE DEVELOPMENT MARKET FOR REAGENTS, BY SEGMENT 92
FIGURE 37 SUPPLEMENTS & GROWTH FACTORS SEGMENT TO GROW AT THE HIGHEST CAGR (13.3%) FROM 2014 TO 2019 93
FIGURE 38 CELL LINE DEVELOPMENT MARKET, BY SOURCE 99
FIGURE 39 THE MAMMALIAN SEGMENT IS POISED TO DOUBLE IN SIZE BY 2019 100
FIGURE 40 WITH WIDE APPLICATION AREAS, MAMMALIAN SEGMENT IS EXPECTED TO HOLD 75% OF THE MARKET IN 2014 102
FIGURE 41 CELL LINE DEVELOPMENT MARKET, BY TYPE 105
FIGURE 42 THE RECOMBINANT CELL LINES SEGMENT IS EXPECTED TO ACCOUNT FOR 68% (2014) OF THE CELL LINE DEVELOPMENT MARKET, BY TYPE 105
FIGURE 43 HYBRIDOMAS IS THE FASTEST-GROWING SEGMENT OF THE CELL LINE DEVELOPMENT MARKET, BY TYPE 109
FIGURE 44 CELL LINE DEVELOPMENT APPLICATIONS MARKET, 2014–2019 113
FIGURE 45 ASIA IS THE FASTEST-GROWING REGION IN THE GLOBAL CELL LINE DEVELOPMENT APPLICATIONS MARKET 114
FIGURE 46 CELL LINE DEVELOPMENT MARKET, BY APPLICATION 115
FIGURE 47 RECOMBINANT PROTEIN THERAPEUTICS IS EXPECTED TO ACCOUNT FOR THE LARGEST SHARE OF 60% (2014) AND IS GROWING AT THE HIGHEST CAGR OF 13.5% 117
FIGURE 48 NORTH AMERICA TO COMMAND THE LARGEST SHARE OF THE GLOBAL CELL LINE DEVELOPMENT MARKET 126
FIGURE 49 U.S. WILL BE THE FASTEST-GROWING COUNTRY OF THE CELL LINE DEVELOPMENT MARKET IN NORTH AMERICA 127
FIGURE 50 GERMANY TO BE THE FASTEST-GROWING COUNTRY OF THE CELL LINE DEVELOPMENT MARKET IN EUROPE 136
FIGURE 51 ASIA IS THE FASTEST-GROWING CELL LINE DEVELOPMENT MARKET 149
FIGURE 52 ROW TO ACCOUNT FOR A SHARE OF 9% OF THE GLOBAL CELL LINE DEVELOPMENT MARKET IN 2014 155
FIGURE 53 COMPANIES ADOPTED AGREEMENTS, PARTNERSHIPS, & COLLABORATIONS AS THE KEY GROWTH STRATEGY OVER THE LAST THREE YEARS 161
FIGURE 54 MARKET SHARE ANALYSIS, BY KEY PLAYER, 2013 162
FIGURE 55 KEY GROWTH STRATEGIES OF THE GLOBAL CELL LINE DEVELOPMENT MARKET, 2011–2014 165
FIGURE 56 BATTLE FOR MARKET SHARE: AGREEMENTS, PARTNERSHIPS, & COLLABORATIONS WAS THE KEY STRATEGY 166
FIGURE 57 GEOGRAPHICAL REVENUE MIX OF TOP 5 MARKET PLAYERS 173
FIGURE 58 AMERICAN TYPE CULTURE COLLECTION: COMPANY SNAPSHOT 174
FIGURE 59 CORNING, INC.: COMPANY SNAPSHOT 178
FIGURE 60 EUROPEAN COLLECTION OF CELL CULTURES: COMPANY SNAPSHOT 182
FIGURE 61 GE HEALTHCARE: COMPANY SNAPSHOT 184
FIGURE 62 LONZA GROUP AG: COMPANY SNAPSHOT 188
FIGURE 63 SARTORIUS AG: COMPANY SNAPSHOT 193
FIGURE 64 SELEXIS SA: COMPANY SNAPSHOT 196
FIGURE 65 SIGMA-ALDRICH CORPORATION: COMPANY SNAPSHOT 200
FIGURE 66 THERMO FISHER SCIENTIFIC, INC.: COMPANY SNAPSHOT 206
FIGURE 67 WUXI APPTEC: COMPANY SNAPSHOT 211

【レポートのキーワード】

細胞株作製装置、培地、血清、試薬、細胞株作製システム、機器、無血清培地

【免責事項】
※当レポート上の情報/データは調査会社が信頼できると判断した情報源から入手したものに基づき作成しましたが、その正確性・完全性を保証するものではありません。当レポートに記載された情報/データ/見解/仮説などは作成時点又は発行時点における調査会社の判断であり、その後の状況変化に応じて変更される場合があります。当レポート上の情報/データに基づいたお客様の意思決定又は実行による結果について、調査会社/発行会社/販売会社H&Iグローバルリサーチ(株)はその責を負いかねますのでご了承ください。英文資料の紹介ページにおける日本語題名/概要/目次はH&Iグローバルリサーチ(株)が翻訳した内容であり、翻訳の正確性・完全性を保証するものではありません。

★調査レポート[細胞株作製の世界市場:細胞株作製装置、培地、血清、試薬]についてメールでお問い合わせはこちら


※世界の市場調査資料 総合販売サイトMarketReport.jpはH&Iグローバルリサーチ株式会社が運営しております。海外進出、グローバル事業戦略策定、新規事業機会の発掘、競合他社の動向把握などに必要な情報やインサイトをお客様にご提供しております。H&Iグローバルリサーチ(登録第5864124号)及びH&I(登録第5783645号)はH&Iグローバルリサーチ株式会社の商標です。
※当サイトでは2016年08月30日現在 204,134 件の調査レポートを取り扱っております。当サイトに掲載していない調査資料も弊社を通してご購入可能ですので、お気軽にご連絡ください。ウェブサイトでは紹介しきれない資料も数多くございます。

◆H&Iグローバルリサーチのお客様(例)◆